Ubs Asset Management Americas Inc Igm Biosciences, Inc. Transaction History

Ubs Asset Management Americas Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$6.66 - $10.64 $3.16 Million - $5.04 Million	-473,882 Reduced 97.7%	11,145 $93,000
Q1 2023 May 15, 2023	BUY	$13.74 - $25.76 $4,506 - $8,449	328 Added 0.07%	485,027 $6.66 Million
Q4 2022 Feb 14, 2023	SELL	$15.45 - $26.02 $612,005 - $1.03 Million	-39,612 Reduced 7.56%	484,699 $8.24 Million
Q3 2022 Nov 14, 2022	SELL	$15.42 - $27.01 $186,551 - $326,766	-12,098 Reduced 2.26%	524,311 $11.9 Million
Q2 2022 Aug 12, 2022	SELL	$13.27 - $25.5 $322,487 - $619,701	-24,302 Reduced 4.33%	536,409 $9.67 Million
Q1 2022 May 16, 2022	BUY	$13.42 - $29.73 $2.68 Million - $5.95 Million	200,032 Added 55.46%	560,711 $15 Million
Q4 2021 Feb 14, 2022	BUY	$27.59 - $66.39 $1.23 Million - $2.97 Million	44,712 Added 14.15%	360,679 $10.6 Million
Q3 2021 Nov 15, 2021	SELL	$65.76 - $90.65 $1.29 Million - $1.78 Million	-19,612 Reduced 5.84%	315,967 $20.8 Million
Q2 2021 Aug 16, 2021	BUY	$57.98 - $96.6 $4.85 Million - $8.08 Million	83,647 Added 33.2%	335,579 $27.9 Million
Q1 2021 May 14, 2021	SELL	$71.56 - $121.23 $3.36 Million - $5.7 Million	-47,018 Reduced 15.73%	251,932 $19.3 Million
Q4 2020 Mar 01, 2021	BUY	$47.41 - $115.03 $9.17 Million - $22.2 Million	193,331 Added 183.05%	298,950 $26.4 Million
Q3 2020 Nov 13, 2020	BUY	$43.0 - $84.01 $1.13 Million - $2.21 Million	26,287 Added 33.14%	105,619 $7.8 Million
Q2 2020 Aug 14, 2020	BUY	$51.3 - $75.21 $4.07 Million - $5.97 Million	79,332 New	79,332 $5.79 Million

21.4M

39.5K

16.5K

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $500M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.